Fr-PPIChem: An Academic Compound Library Dedicated to Protein-Protein Interactions.
Bosc N, Muller C, Hoffer L, Lagorce D, Bourg S, Derviaux C, Gourdel ME, Rain JC, Miller TW, Villoutreix BO, Miteva MA, Bonnet P, Morelli X, Sperandio O, Roche P
Thomas Miller
Group leader Responsable scientifique Biography Thomas holds a PhD in chemistry from UCLA and was awarded a cancer research training fellowship to study biochemistry and tumor-immunobiology at the National Cancer Institute.
He is currently a Principal Investigator in the Drug Discovery Unit at the Institut Paoli-Calmettes (IPC) and member of the Integrated Structural and Chemical Biology (iSCB) Team at the Cancer Research Center Marseille (CRCM) in France. Thomas is also co-coordinating the industrial partnership program at IPC tasked with accelerating the development of therapeutic innovations for IPC patients.
Prior to joining IPC, Thomas co-founded Paradigm Shift Therapeutics to discover and develop innovative immunotherapies for cancer treatment. Through this venture Tom and his colleagues pioneered novel public private partnership models to access cutting edge technologies and more equitably share risk with larger stakeholders resulting in more affordable and accessible therapies for patients. Their immune checkpoint inhibitor program is an awardee of the National Institutes of Health to support a multicenter collaboration between the National Cancer Institute (US), Institut Paoli-Calmettes (FR), and Paradigm Shift Therapeutics.
Thomas is passionate about mentoring young scientists, using chemistry to interpret biology, and translating discoveries into better outcomes for patients.
He is currently a Principal Investigator in the Drug Discovery Unit at the Institut Paoli-Calmettes (IPC) and member of the Integrated Structural and Chemical Biology (iSCB) Team at the Cancer Research Center Marseille (CRCM) in France. Thomas is also co-coordinating the industrial partnership program at IPC tasked with accelerating the development of therapeutic innovations for IPC patients.
Prior to joining IPC, Thomas co-founded Paradigm Shift Therapeutics to discover and develop innovative immunotherapies for cancer treatment. Through this venture Tom and his colleagues pioneered novel public private partnership models to access cutting edge technologies and more equitably share risk with larger stakeholders resulting in more affordable and accessible therapies for patients. Their immune checkpoint inhibitor program is an awardee of the National Institutes of Health to support a multicenter collaboration between the National Cancer Institute (US), Institut Paoli-Calmettes (FR), and Paradigm Shift Therapeutics.
Thomas is passionate about mentoring young scientists, using chemistry to interpret biology, and translating discoveries into better outcomes for patients.